JP2023512783A5 - - Google Patents

Info

Publication number
JP2023512783A5
JP2023512783A5 JP2022547874A JP2022547874A JP2023512783A5 JP 2023512783 A5 JP2023512783 A5 JP 2023512783A5 JP 2022547874 A JP2022547874 A JP 2022547874A JP 2022547874 A JP2022547874 A JP 2022547874A JP 2023512783 A5 JP2023512783 A5 JP 2023512783A5
Authority
JP
Japan
Prior art keywords
approximately
gaa
use according
individual
oligosaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022547874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512783A (ja
JP7804582B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/017113 external-priority patent/WO2021159092A1/en
Publication of JP2023512783A publication Critical patent/JP2023512783A/ja
Publication of JP2023512783A5 publication Critical patent/JP2023512783A5/ja
Priority to JP2025138630A priority Critical patent/JP2025166240A/ja
Application granted granted Critical
Publication of JP7804582B2 publication Critical patent/JP7804582B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022547874A 2020-02-08 2021-02-08 ポンペ病を処置するための組成物および方法 Active JP7804582B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025138630A JP2025166240A (ja) 2020-02-08 2025-08-22 ポンペ病を処置するための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062971930P 2020-02-08 2020-02-08
US62/971,930 2020-02-08
US202063115975P 2020-11-19 2020-11-19
US63/115,975 2020-11-19
PCT/US2021/017113 WO2021159092A1 (en) 2020-02-08 2021-02-08 Compositions and methods for treating pompe disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025138630A Division JP2025166240A (ja) 2020-02-08 2025-08-22 ポンペ病を処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2023512783A JP2023512783A (ja) 2023-03-29
JP2023512783A5 true JP2023512783A5 (https=) 2024-02-16
JP7804582B2 JP7804582B2 (ja) 2026-01-22

Family

ID=74853758

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547874A Active JP7804582B2 (ja) 2020-02-08 2021-02-08 ポンペ病を処置するための組成物および方法
JP2025138630A Pending JP2025166240A (ja) 2020-02-08 2025-08-22 ポンペ病を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025138630A Pending JP2025166240A (ja) 2020-02-08 2025-08-22 ポンペ病を処置するための組成物および方法

Country Status (12)

Country Link
US (2) US12251430B2 (https=)
EP (1) EP4100120A1 (https=)
JP (2) JP7804582B2 (https=)
KR (1) KR20220139936A (https=)
CN (1) CN115715218A (https=)
AU (1) AU2021216055A1 (https=)
BR (1) BR112022015505A2 (https=)
CA (1) CA3167091A1 (https=)
IL (1) IL295415A (https=)
MX (1) MX2022009753A (https=)
WO (1) WO2021159092A1 (https=)
ZA (1) ZA202209925B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022009753A (es) 2020-02-08 2022-09-07 Genzyme Corp Composiciones y metodos para el tratamiento de la enfermedad de pompe.
EP4164678A1 (en) 2020-06-14 2023-04-19 Genzyme Corporation Compositions and methods for treating late-onset pompe disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
EP1877099B1 (en) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
WO2008089403A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
CN102369023A (zh) 2008-12-16 2012-03-07 建新公司 寡糖-蛋白缀合物
SG194802A1 (en) 2011-05-16 2013-12-30 Genzyme Corp Induction of immune tolerance by using methotrexate
WO2016149508A1 (en) * 2015-03-19 2016-09-22 Shire Human Genetic Therapies, Inc. Mrna therapy for pompe disease
KR20250007693A (ko) * 2015-12-30 2025-01-14 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
MX2022009753A (es) 2020-02-08 2022-09-07 Genzyme Corp Composiciones y metodos para el tratamiento de la enfermedad de pompe.

Similar Documents

Publication Publication Date Title
RU2626512C2 (ru) Концентрированные белковые фармацевтические составы и их применение
ES2993153T3 (en) Pan elr+ cxc chemokine antibodies
CN1829532A (zh) 肌肉抑制素（gdf8）抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途
US12065494B2 (en) Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CN1466464A (zh) 癌症治疗药
CN111265531A (zh) 治疗和预防移植物抗宿主病的方法
BR112021010789A2 (pt) Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar
JP2023512783A5 (https=)
Fudenberg Are autoimmune diseases immunologic deficiency states?
JP2018515493A5 (https=)
JP2018522028A (ja) ブルトン型チロシンキナーゼ阻害剤の組み合わせ及びそれらの使用
ES2681195T3 (es) Utilización de la proteína de fusión TACI-Ig, tal como atacicept, para la fabricación de un medicamento para el tratamiento de lupus eritematoso
JP2022116305A (ja) 抗体含有製剤
JPH05508636A (ja) 免疫システム機能不全に関連する障害の予防及び治療のための免疫システム安定剤
Passwell et al. Inter-mouse strain differences in macrophage function and its relationship to antibody responses
Gillis et al. Six refractory lupus patients treated with rituximab: a case series
JP2024023347A (ja) ＴＮＦα関連疾患の治療方法
TWI775333B (zh) 治療癌症之方法
ES3009417T3 (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
JP2023552773A5 (https=)
JP4370117B2 (ja) 化学物質過敏症治療薬
US20250230238A1 (en) Methods and compositions for treating systemic lupus erythematous (sle)
WO2025209479A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
DE LIA et al. Digoxin therapy in the fetus
US20250223356A1 (en) Methods and compositions for treating relapsing multiple sclerosis